Public Sector Pension Investment Board Increases Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Public Sector Pension Investment Board increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 8.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,999 shares of the medical instruments supplier’s stock after acquiring an additional 3,379 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.20% of LeMaitre Vascular worth $3,620,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Shaker Investments LLC OH raised its position in shares of LeMaitre Vascular by 1.3% during the 1st quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock worth $906,000 after purchasing an additional 169 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 199 shares in the last quarter. nVerses Capital LLC boosted its stake in shares of LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares during the last quarter. Albion Financial Group UT boosted its stake in shares of LeMaitre Vascular by 5.6% in the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock worth $264,000 after acquiring an additional 212 shares during the last quarter. Finally, Texas Permanent School Fund Corp raised its stake in LeMaitre Vascular by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after purchasing an additional 225 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The disclosure for this sale can be found here. Insiders have sold 43,251 shares of company stock worth $3,714,994 over the last ninety days. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

LMAT stock opened at $91.71 on Friday. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $92.90. The firm has a market cap of $2.06 billion, a PE ratio of 60.74, a PEG ratio of 2.41 and a beta of 0.88. The firm’s 50 day moving average price is $87.18 and its 200-day moving average price is $78.62.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.37 earnings per share. Equities research analysts predict that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were given a dividend of $0.16 per share. The ex-dividend date was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.70%. LeMaitre Vascular’s payout ratio is currently 42.38%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LMAT shares. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. JMP Securities increased their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Lake Street Capital began coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 target price on the stock. Roth Mkm restated a “buy” rating and issued a $100.00 price target on shares of LeMaitre Vascular in a research report on Friday, May 31st. Finally, Barrington Research reiterated an “outperform” rating and set a $92.00 price objective on shares of LeMaitre Vascular in a research report on Friday, September 20th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $94.40.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.